Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor by 노태웅 et al.
Visually Discernible [18F]Fluorodeoxyglucose Uptake
in Papillary Thyroid Microcarcinoma: A Potential New
Risk Factor
Mijin Yun, Tae-Woong Noh, Arthur Cho, Yun-Jung Choi, Soon-Won Hong,
Cheong-Soo Park, Jong-Doo Lee, and Chun K. Kim
Division of Nuclear Medicine (M.Y., A.C., Y.-J.C., J.-D.L.), Department of Radiology, and Departments of
Internal Medicine (T.-W.N.), Pathology (S.-W.H.), and Surgery (C.-S.P.), Yonsei University College of
Medicine, Seoul, Korea 120-752; and Division of Nuclear Medicine and Molecular Imaging (M.Y.,
C.K.K.), Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston,
Massachusetts 02115
Context: A significant number of papillary thyroid microcarcinomas (PTMCs), despite excellent
prognosis, show aggressive features such as extrathyroidal extension (EE) and lymph node metas-
tasis (LNM) that may not always be detected preoperatively or intraoperatively. The relapse rate
appears also substantial.
Objective: To assess the value of [18F]fluorodeoxyglucose (FDG) uptake in PTMC as a potential risk
factor for preoperative risk stratification.
Methods: This retrospective study included 87 patients (17males and 70 females; mean age 51.2
yr, range 29–74 yr) with a unifocal PTMC who underwent preoperative FDG-positron emission
tomography (PET)/computed tomography (CT)and total thyroidectomy and central lymph node
dissection. Statistical analyses were performed to compare the gender, age, tumor size, and FDG
uptake in PTMC with the presence of histopathologically proven EE and central LNM (cLNM).
Results: Of the 87 patients, 44 (51%) had EE, and 27 (31%) had cLNM. PET/CT showed visually
discernible FDGuptake in46PTMCs (53%). FDGpositivityofPTMCswas theonly significant variable
correlated with both EE and cLNM; there was a significant difference in the prevalence of both EE
(70 vs. 29%) and cLNM (41 vs. 19.5%) between the FDG-positive and FDG-negative groups. In
contrast,otheralreadyknownrisk factors, i.e.gender, age,andsize, showedacorrelationwithonly
one or neither of EE and cLNM.
Conclusion: The results indicate that visual FDGpositivity in PTMCs is apotential risk factor that canbe
useful for preoperative risk stratification. Prospective studieswould bewarranted to assess the long-term
benefit and cost effectiveness of preoperative FDG-PET/CT. (J Clin EndocrinolMetab 95: 3182–3188, 2010)
High-resolution ultrasound-guided fine needle aspira-tion biopsy has led to a rapid rise in the incidence of
papillary thyroid microcarcinoma (PTMC), i.e. papillary
thyroid carcinoma 1 cm or smaller. PTMCs have been
largely perceived as tumors that are characterized by be-
nign behavior, of little clinical significance, and do not
affect patients’ survival.However, it has been increasingly
demonstrated that PTMCs show very diverse disease ex-
tent with widely varying reported frequencies of the ag-
gressive features (1–5). In addition, the tumor character-
istics, age-based recurrence rates, and/or prevalence of the
aggressive features in patientswith PTMCat diagnosis are
reported to be similar to that in patients with larger pap-
illary thyroid carcinomas (1, 6).Also, despite an extremely
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low risk for mortality, recurrent or persistent disease even
after total ornear-total thyroidectomy is surprisingly com-
mon, and some authors feel that the treatment of patients
with PTMC should be no different from the treatment of
patients with papillary macrocarcinoma (7, 8).
The extent of thyroid surgery for PTMC varying from
a lobectomy alone to total thyroidectomy with central-
compartment neck dissection is largely determined de-
pending on the presence or absence of the risk factors/
aggressive features (9). Therefore, the wide variability in
the reported prevalence of aggressive features among dif-
ferent studies as well as no significant difference in the
prevalenceof aggressive features betweenmicro- andmac-
rocarcinomas are of concern, especially given that some of
these histopathological featuresmaynot easily be detected
by preoperative imaging or even by inspection at the time
of surgery.
[18F]Fluorodeoxyglucose (FDG) uptake in many ma-
lignant tumors on positron emission tomography (PET)
has been shown to be a significant predictor of greater
aggressiveness and a poorer prognosis (10–13). Also, in
post-thyroidectomy thyroid cancer patients, radioiodine-
negative/FDG-positive recurrences are known to be asso-
ciated with dedifferentiated tumors and a grave prognosis
(14–16). This well-known relationship between the FDG
avidity and tumor aggressiveness/differentiation appears
to be in line with the limited sensitivity of preoperative
FDG PET in ruling in malignancy in patients with thyroid
nodules because the majority of them are well differenti-
ated (17). At the same time, it is quite perplexing and
equally interesting that a large number of thyroid cancers,
including incidentalomas and PTMCs, exhibit increased
FDG uptake despite their well-differentiated histology.
In addition, we observed that small nodules of 5 mm or
smaller often showed increased FDG uptake, whereas
those close to 10 mm or even some macrocarcinomas
not included in this study exhibited no or minimal up-
take. Constellation of these well-known facts and ob-
servations prompted us to speculate that FDG positivity
may represent relative aggressiveness even in well-dif-
ferentiated PTMCs.
The objective of this retrospective study was to: 1) as-
sess the frequency of visual FDG positivity in PTMCs and
2) to compare the prevalence of extrathyroidal extension
and lymph node metastasis between patients with FDG-
positive and -negative PTMCs.
Patients and Methods
Patients (Table 1)
Our institutional review board approved the protocol for this
retrospective study. The medical records of 4615 patients who
underwent a total thyroidectomy with central lymph node dis-
section between 2005 and 2008 were reviewed, and 2311 pa-
tients had a diagnosis of PTMC. Of the 2311 patients with
PTMC,145patients hadaPETscanwithin3monthsbefore their
surgery. Of the 145 patients, 10 patients had FDG PET for
screening of cancer that eventually led to the diagnosis of PTMC,
whereas FDG PETwas performed after PTMCs were diagnosed
in the other 134 patients. These 10 patients were excluded be-
cause they represent a different group, introducing bias to the
data. Patients who had a diagnosis of PTMC before PET were
advisedof theavailabilityofPET, its cost, potential butunproven
benefit and efficacy of PET in the setting of PTMC, and possible
benefit of finding second primary malignancies with PET re-
ported in the literature.Of them, 134 patients elected to undergo
PET imaging studies. Therefore, the 134 patients effectively rep-
resent a randomly selected population.Of the 134patients, three
groups of patients were additionally excluded to avoid bias.
Eight patients were excluded because of a previous history of
malignancies in the head and neck. Thirty patients with multi-
focal carcinomaswere excluded because it would not be possible
to determine which one(s) of the multiple nodules is (are) re-
sponsible for lymph node metastases, if present. And, if the de-
gree of FDG uptake varies among these multiple nodules, the
relationship between the FDG uptake and lymph node metasta-
ses cannot be determined. Lastly, 10 patients showing diffuse,
nonfocal FDG uptake in their thyroid were excluded because
FDG uptake by thyroid carcinomas may not be accurately mea-
sured. The remaining 87 patientswith pathologically confirmed,
unifocal PTMCconstitute the studypopulation (17males and70
females; mean age 51.2 yr, range 29–74 yr).
Imaging procedures
PET/computed tomography (CT) imageswere acquired using
the Phillips Gemini PET/CT scanner (Phillips-ADAC Medical
Systems, Cleveland, OH). Patients were instructed to fast for
more than 6 h, and then 5.18MBq (0.14mCi)/kg of FDGwas iv
injected into these patients. Images from the skull base to the
proximal thigh were acquired 1 h later. Emission images were
acquired for 3 min per bed, and transmission scans from low-
dose CT were used for attenuation correction. Images were
then reconstructed using the low-action maximal-likelihood
algorithm.
Image interpretation and semiquantitative analysis
Two experienced nuclear medicine specialists visually re-
viewed PET/CT images using the Syntegra program (version
2.1E) and performed semiquantitative analysis on the nodules.
The nuclear medicine specialists were blinded to the patients’
TABLE 1. Clinical and histopathological characteristics
in 87 patients with PTMC
No. of patients
Age (45 yr/45 yr) 60 (69%)/27 (31%)
Sex (male/female) 17 (20%)/70 (80%)
Family history (present) 6 (7%)
Radiation history (present) 0 (0%)
Tumor size (5 mm/5 mm) 44 (51%)/43 (49%)
Extrathyroidal extension (present) 44 (51%)
Central lymph node metastasis (present) 27 (31%)
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clinical status/surgical pathology; they knew only that the pa-
tients were diagnosed with thyroid cancer.
FDG uptake in PTMCswas visually categorized as positive if
there was a discernible focal FDG uptake and negative if there
was no discernibly higher FDGuptake than surrounding thyroid
tissue. For semiquantitative analysis, a region of interest was
drawn around these microcarcinomas, and the peak standard
uptake value (SUV) was recorded. When a nodule was not vi-
sually discernible on PET, a region of interest was drawn ac-
cording to the location of the nodule based on other anatomical
images. Any central lymph node with visually discernible FDG
uptake was considered to be positive for metastasis. Lymph
nodes in level VI were considered to be central lymph nodes,
according to the guidelines of the American Head and Neck
Society (18).
Statistical analysis
Statistical analyses were performed using Statistical Package
for Social Sciences (version 12.0; SPSS Inc., Chicago, IL). Uni-
variate analyses were performed to determine the relationship
between four independent variables, i.e. gender, age, tumor size,
and FDG uptake in the PTMC, and two dependent variables,
extrathyroidal extension (presence or absence) and central
lymph nodemetastasis. All four independent and two dependent
variables were dichotomized by gender (male or female), age
(45 or 45 yr), tumor size (5 or 5 mm), and visually dis-
cernible focal FDG uptake in the PTMC (presence or absence),
extrathyroidal extension (presence or absence), and central
lymph node metastasis (presence or absence). Three of the four
independent variables, i.e. age, tumor size, and FDG uptake ex-
pressed as SUV, as continuous variables were also correlated
with the two dichotomized dependent variables.
Additionally, the relationship between dichotomized inde-
pendent and dependent variables were assessed by two-tailed
Fisher’s exact test. Two-tailed independent Student’s t test was
used to assess thedifference in the age and tumor size between the
dichotomized groups of dependent variables. To assess the dif-
ference in the SUVs between the dichotomized groups of depen-
dent variables, Mann-WhitneyU test was used. For comparison
of two continuous variables, Pearson’s correlation analysis was
performed.
Independent variables with a P  0.25 identified from the
univariate analysis or Fisher’s exact test were included in the
multivariate logistic regression analysis to assess possible inter-
dependency. When both dichotomized and continuous variable
of the same independent factor had a P  0.25, then the more
significant one of the two was chosen for multivariate analysis.
The results were considered statistically different if the P value
from the multivariate analysis was less than 0.05 and the 95%
confidence interval of the odds ratio did not include 1. The sen-
sitivity, specificity, positive predictive value, and negative pre-
dictive value of FDG positivity for prediction of the extrathy-
roidal extension and/or central lymph nodemetastasis were also
calculated.
Results
Comparison of independent variables with
extrathyroidal extension (Table 2)
Of the 87 PTMCs, 44 nodules (51%) were pathologi-
cally confirmed to have extrathyroidal extension. Table 2
provides the results from various analyses of the dichot-
omized and/or continuous independent variables with ex-
trathyroidal extension. The gender and age were not
significant independent variables. Also, there was no dif-
ference in the agebetween44patientswith and43patients
without extrathyroidal extension (mean age 50.8 9.3








Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
Gender
Female 35 (50%) 35 (50%) 1
Male 8 (47.1%) 9 (52.9%) 1.125 (0.389–3.252) 0.837,a 1.0b
Age
45 yr 14 (51.9%) 13 (48.1%) 1
45 yr 29 (48.3%) 31 (51.7%) 1.151 (0.464–2.857) 0.761,a 0.819b
Age (continuous variable) 0.993 (0.954–1.034) 0.743a
Tumor size
5 mm 32 (74.4%) 11 (25.6%) 1





Negative 29 (70.7%) 12 (29.3%) 1




CI, Confidence interval; OR, odds ratio.
a By univariate logistic regression analysis.
b By Fisher’s exact test.
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and 51.6 11.9 yr, respectively, P 0.74 by Student’s
t test).
The size of PTMC tumors based on histopathological
specimen ranged from 2–10 mm with a mean size of 5.6
mm; 44 tumors were larger than 5 mm, and 43 tumors
were 5 mm or smaller. There was a significant difference
in the frequency of extra-thyroidal extension between
the  5 mm and  5 mm groups (75% vs. 26%, P 
0.000005 by the Fisher’s exact test). The tumor size in
patients with extrathyroidal extension was significantly
larger than thosewithout extension (mean size6.82.0
cm vs. 4.3  2.2, P  0.0001 by Student’s t test).
On visual analysis of PET scans, 46 (53%) of the 87
PTMCs showed discernible FDG uptake, and 41 did not.
Extrathyroidal extensionwas present in 70%(32of 46) of
the FDG-positive group comparedwith 29% (12 of 41) in
the FDG-negative group (P 0.0001). The SUVs in all 87
PTMCs ranged from 0.7–15.0 with a median of 2.1. The
median SUV in 44 patients with extrathyroidal extension
was 2.8 compared with 1.8 in 43 patients without exten-
sion (P  0.0021 by the Mann-Whitney U test). Multi-
variate logistic regression analysis revealed that dichoto-
mized tumor size and visual FDG positivity were two
significant independent variables correlated with extra-
thyroidal extension (Table 2).
Even in a selected group of patients that is considered
to be a low-risk group, i.e. 23 female patients age 45 yr or
younger, visual FDGpositivity and tumor size were found
to be significant variables. Nine of 14 patients with visual
FDG positivity in the PTMCs were associated with extra-
thyroidal extension compared with one of nine patients
without extension (P  0.013). Ten of 12 patients with
tumor size larger than 5 mm were associated with extra-
thyroidal extension compared with three of eight patients
with tumor 5 mm or smaller (P  0.013).
The sensitivity, specificity, positivepredictive value and
negative predictive value of visual FDGpositivity for eval-
uation of extrathyroidal extension in all 87 patients were
73, 67, 70, and 71%, respectively.
Comparison of independent variables with central
lymph node metastasis (Table 3)
There were 27 (31%) patients with pathologically con-
firmed central lymph node metastasis. Table 3 shows the
results from univariate and multivariate analyses. Among
the independent variables, visual FDG positivity in the
PTMCswas found to be the only significant variable mul-
tivariate analysis. The frequency of central lymph node
metastasis in the FDG positive group was 41% (19 of 46)
compared with 20% (eight of 41) in the FDG-negative
group (P  0.037). The sensitivity, specificity, positive
predictive value, and negative predictive value of FDG
uptake for the diagnosis of central lymph node metastasis
were 70, 55, 41, and 80%, respectively. The tumor size as
continuous variable nearly approached the statistical sig-
nificance byunivariate analysis (P0.063) butwas found
to be completely insignificant by subsequent multivariate
analysis (P  0.534).
Miscellaneous
PET/CT showed foci of increased FDG uptake, sug-
gesting central lymph node metastases in only two of the
27 patients with confirmed lymph node disease. In the
remaining 60 patients without central lymph node metas-








Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
Gender
Female 51 (72.9) 19 (27.1) 1
Male 9 (52.9) 8 (47.1) 2.386 (0.804–7.085) 0.121,a 0.145b 3.241 (0.936–11.220) 0.064
Age
45 20 (74.1) 7 (25.9) 1
45 40 (66.7) 20 (33.3) 1.429 (0.518–3.940) 0.485,a 0.618b
Age (continuous variable) 0.995 (0.953–1.039) 0.816a
Tumor size
5 mm 32 (74.4) 11 (25.6) 1
5 mm 28 (63.7) 16 (36.3) 1.662 (0.662–4.171) 0.276,a 0.257b
Tumor size (continuous variable) 1.200 (0.983–1.460) 0.063a 1.072 (0.861–1.335) 0.534
FDG visual uptake
Negative 33 (80.5) 8 (19.5) 1
Positive 27 (58.7) 19 (41.3) 2.903 (1.100–7.658) 0.026,a 0.037b 3.298 (1.049–10.372) 0.041
FDG SUVs (continuous variable) 1.065 (0.881–1.287) 0.52a
CI, Confidence interval; OR, odds ratio.
a By univariate logistic regression analysis.
b By Fisher’s exact test.
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tasis, the PET/CT was false positive in one and true neg-
ative in 59 cases. In all 87 patients, PET/CT showed no
abnormalities outside the cervical region.
There appeared to be a moderate dependency of SUV
on tumor size (y 0.4462 0.4592x,where y SUVand
x  tumor size in millimeters; r  0.0478; P  0.001).
Nevertheless, the tumor SUVs widely varied even among
nodules of similar sizes. Furthermore, as shownabove, the
tumor SUV and size were found to be independent vari-
ables for the extrathyroidal extension by multivariate
analysis. This seemingly dependent relationship between
the SUV and tumor sizemost likely resulted from thewell-
knownpartial volume effect. This issue is discussedbelow.
Discussion
Despite a very favorable prognosis, there is awide variability
in the clinical and pathologic characteristics of PTMCat the
time of diagnosis among different studies, i.e. the prevalence
of bilateral and/or multiple foci being observed in 2.9–
56.8% and extracapsular invasion and/or lymph node me-
tastasis at diagnosis ranging fromnearly 0%up toover 60%
(2–4, 19).Moreover, in a recent report analyzingmore than
6000 patients with papillary thyroid carcinoma, microcar-
cinomas showed similar features to macrocarcinomas with
respect to tumor characteristics and age-based recurrence
rates (6). Another study also found no significant difference
in the prevalence of multifocality, extrathyroidal extension,
and lymph node metastasis in patients with PTMC at diag-
nosis compared with that in patients with larger papillary
thyroid carcinomas (1). The relapse rate in patients with
PTMCs is also substantial (7, 20, 21).
According to new 2009American Thyroid Association
guidelines, a thyroid lobectomyalonemaybe sufficient for
PTMCwithout other risk factors (9). However, some au-
thors seem to favor more aggressive surgery for patients
with PTMC, despite its small size, as for those with pap-
illary thyroid macrocarcinoma (7, 8, 22). Despite these
different preferences among studies, most investigators
seem to agree that preoperative risk stratification is im-
portant in determining the extent of surgery.
Theknown risk factors for the recurrent disease include
the gender, age, tumor size, multifocality, extrathyroidal
extension, and lymph node metastasis, although the sig-
nificance level of individual factors varies among different
reports (4, 5, 7, 19, 23–25). Moreover, some of the his-
topathological risk factors are often undetected preoperatively
by imagingorclinically,orevenbyintraoperative inspection(4,
26). Therefore, it would certainly be desirable to have a risk
factor that can be easily assessed preoperatively.
Although FDG positivity in recurrent thyroid cancer is
well known to indicatemore aggressive behavior (14–16),
it is still unclear whether or not FDG positivity of primary
well-differentiated thyroid cancers in the preoperative set-
ting similarly indicates tumor aggressiveness. Jeong et al.
(4) recently reported that SUVof PTMCs did not correlate
with the presence of lymphaticmetastasis, themultiplicity
of primary tumor, or extrathyroid invasion but correlated
only with the size of PTMCs. There is a remarkable sim-
ilarity between our data and theirs, which is the moderate
dependency of SUVon the tumor sizewith nearly identical
r values (0.479 in our study and 0.481 in the previous
study). However, measured SUV of lesions smaller than 3
cm falsely declines (especially more so when 2 cm),
which is well known as the partial volume effect (27–29).
For example, the measured activity of a 1-cm lesion is less
than 50% of that of a 2-cm lesion despite the same con-
centration of activity in both lesions. We strongly believe
that the seemingly significant dependency of SUV on the
tumor size in both studies merely represents the partial
volume effect rather than a true dependency. Instead of
SUV, visual assessment is often relied upon for interpre-
tationof small lesions. For example, SUVof 2.5 is themost
widely adopted cutoff for differentiating malignant from
benign pulmonary nodules. However, based on the expe-
rience accumulated over more than 10 yr, visually dis-
cernible FDGactivity, regardless of SUV, in a small nodule
is now generally considered suspicious for malignancy.
Likewise, we suspected that visual analysis could be more
meaningful than SUV for PTMC,which indeed turned out
to be the case.
We found visually discernible FDG uptake in 53% of
PTMCs. The sensitivity, specificity, positive predictive
value, and negative predictive value of visual FDG posi-
tivity for extrathyroidal extension were 73, 67, 70, and
71%, respectively, and 70, 55, 41, and 80%, respectively,
for central lymph node metastasis. Given these rela-
tively low values, FDG positivity in PTMC cannot be
used as a single predictor for extrathyroidal extension
and central lymph node metastasis. Nevertheless, there
was a significant difference in the prevalence of both EE
(70 vs. 29%) and cLNM (41 vs. 19.5%) between the
FDG-positive and FDG-negative groups. On the other
hand, other known risk factors, i.e. gender, age, and
size, showed a correlation with only one or neither of
the extrathyroidal extension and central lymph node
metastasis. These results suggest that FDG positivity
can be as good as or possibly even better than other
known risk factors for preoperative risk stratification in
patients with PTMC.
One of the limitations of our study is lack of direct
correlation of FDG positivity in PTMCs with disease re-
lapse rate because the follow-up is not long enough. Even
after several more years of follow-up, we may still be un-
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able to find any significant difference in the relapse rate
between FDG-positive and FDG-negative groups because
all our patients in both groups underwent extensive sur-
gery, i.e. total thyroidectomywith lymph node dissection.
In low-risk patients, it would be interesting to carry out
prospective studies comparing recurrence rates between
an FDG-negative group undergoing lobectomy and an
FDG-positive group undergoing lobectomy, and/or be-
tween an FDG-positive group undergoing lobectomy
and an FDG-positive group undergoing more extensive
surgery.
PET/CT is an expensive procedure. However, its long-
term cost effectiveness is unknown. Although the mortal-
ity rate associated with PTMCs is extremely low even in
the presence of extended disease, the recurrence rate is not
(7, 8). When the disease relapses, additional diagnostic
and appropriate therapeutic procedures, which may in-
clude reoperation, will be required. This will, in turn,
translate into increasing cost. In addition, there will be
uncalculated cost due to the patient’s decreased produc-
tivity resulting fromhypothyroidismand time required for
the diagnostic work-up and treatment. Perhaps evenmore
importantly, the patients will suffer from psychological
stress from having recurrent malignancy. Therefore, if
positive clinical impact of a preoperative PET/CT exam-
ination can be demonstrated by prospective studies, this
proceduremay possibly turn out to be cost effective rather
than expensive, despite its high initial cost. Assessment of
long-term cost effectiveness also seems to warrant a pro-
spective evaluation.
Other than the potential value of FDG positivity in the
primary tumor, the yield of whole-body PET/CT in pa-
tients with PTMCs appears to be quite low. To date, de-
tection of microscopic lymph node disease in malignant
tumors has been a challenge for any diagnostic imaging
modalities. The sensitivity andnegative predictive value of
PET for diagnosis of regional lymphnodedisease basedon
FDG uptake in the lymph node as the criteria was ex-
tremely low in our study as expected. The yield of PET/CT
for evaluation of the rest of the whole body, regardless of
its diagnostic efficacy, seems very low in patients with
PTMCs simply because of the extremely lowprevalence of
distant metastatic disease in this population.
Conclusion
Visually discernible FDG uptake was observed in ap-
proximately one half of the unifocal PTMCs and associ-
ated with a significantly higher prevalence of extrathy-
roidal extension and central lymph node involvement
compared with the FDG-negative group. This indicates
that FDG positivity is a potential new risk factor that can
be useful for preoperative risk stratification. Prospective
studieswould bewarranted to assess the long-termbenefit
and cost effectiveness of preoperative FDG-PET.
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